Cost-effectiveness of Metronomic chemotherapy vs Weekly Intravenous Paclitaxel in patients with ER+/HER2-Metastatic Breast Cancer

Author:

Ren Ning,Xu Qiaoping,Ren Lanqi,Yang Yibei,Pan Junjie

Abstract

Abstract Objective:To compare the cost-effectiveness of Metronomic Oral Vinorelbine plus Cyclophosphamide and Capecitabine(VEX) and Weekly Intravenous Paclitaxel (P) in patients with Estrogen Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer (MBC). Methods:The Markov model was established to simulate the patients receiving metronomic chemotherapy (VEX regimen) and Weekly Intravenous Paclitaxel. The results of clinical trials and other published literature were comprehensively used to evaluate the cost-effectiveness ratio of the two chemotherapy regimens, and sensitivity analyses were conducted. Results:The QALYs of VEX and P regimen were 1.85 and 1.45, respectively, and the ICERs were $40 333.69/QALY and $4 152.09/QALY, respectively. In China, the total cost of VEX regimen is $74 617.32, while the total cost of P regimen is $6 020.53. The cost of P regimen is much lower than that of the VEX regimen. In addition, the VEX is more effective than the P, with higher TTF and PFS, and higher disease control rates. Sensitivity analysis shows that P regimen has a more cost-effective advantage in China. The analysis of incremental cost-effectiveness shows that with VEX as the reference group, P regimen is the preferred option. Conclusions:Compared with VEX, P regimen is more cost-effective as a first-line treatment for ER+/HER2- metastatic breast cancer from the perspective of Chinese health service system.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3